After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.

Donanemab can slow the progression of Alzheimer’s disease.But what is the drug and how does it work? Here your questions on ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...

At the end of October, Nice declined to approve this drug for use on the NHS for treating early-stage Alzheimer's disease.

New treatments for Alzheimer disease don’t reverse cognitive symptoms, but they do significantly slow progression. Evidence suggests that earlier treatment is most effective.

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

The MHRA have approved donanemab for the treatment of Alzheimer’s disease. However, NICE does not recommend use on the NHS ...

Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the ...

Donanemab is a targeted antibody drug which slows the early stages of Alzheimer’s. Alzheimer’s Research UK said Nice's announcement “risks signalling that the UK is no longer a good place to launch ...

A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...